



## **LASA SUPERGENERICS LIMITED**

**CORPORATE OFFICE:** B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India,  
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

**Ref. No.: LASA/SE/20-21/11**

**Wednesday June 10, 2020**

<b>To,</b> <b>Corporate Services Department</b> <b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001.</b> <b>BSE CODE –540702</b>	<b>To,</b> <b>Corporate Services Department</b> <b>National Stock Exchange of India Limited</b> <b>“Exchange Plaza”, Plot No. C/1,</b> <b>G Block Bandra-Kurla Complex,</b> <b>Bandra (E), Mumbai – 400 051.</b> <b>NSE CODE: LASA</b>
--	--

Dear Sir/Madam,

**Sub: Update on Financial Results**

Further to our outcome of Board Meeting held on June 05, 2020 we are enclosing signed Audited Financial Results for the Quarter and Year ended March 31, 2020 along with Statement of Assets and Liabilities, Cash Flow statement & Audit Report for the year ended March 31, 2020.

Further, apart from sign taken on financials there are no other / material change made by the company in Audited financials for the year ended March 31, 2020.

Request you to take the same on your records.

Thanking you  
Yours Sincerely  
FOR **LASA SUPERGENERICS LIMITED**

**NIDHI KULSHRESHTHA**  
**COMPANY SECRETARY AND COMPLIANCE OFFICER**

Statement of Audited Financial Results for Quarter and Year ended 31st March, 2020

(Rs. In Lakhs)

Particulars	Quarter ended			Year ended	
	31.03.2020 (Audited)	31.12.2019 (Unaudited)	31.03.2019 (Audited)	31.03.2020 (Audited)	31.03.2019 (Audited)
<b>1. INCOME</b>					
a. Revenue from Operations	4,858.56	3,928.97	4,202.38	16,727.12	16,957.30
b. Other Income	6.17	2.58	35.75	23.16	47.45
<b>Total Income</b>	<b>4,864.73</b>	<b>3,931.54</b>	<b>4,238.13</b>	<b>16,750.28</b>	<b>17,004.75</b>
<b>2. Expenses</b>					
a. Cost of Materials consumed	2,493.91	1,931.24	2,288.79	8,651.33	8,380.65
b. Cost of Traded Goods	-	-	884.07	49.41	4,240.38
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	(262.39)	245.85	(183.74)	764.52	173.62
d. Employee benefits expenses	342.09	350.80	321.65	1,341.60	1,173.51
e. Finance costs	229.91	166.51	167.94	810.42	837.88
f. Depreciation & amortizations expenses	435.82	439.65	478.43	1,733.90	1,930.85
g. Other Expenses	1,382.31	562.84	584.05	2,925.49	1,878.14
<b>Total Expenses (a to g)</b>	<b>4,621.65</b>	<b>3,696.89</b>	<b>4,541.20</b>	<b>16,276.66</b>	<b>18,615.03</b>
Exceptional Items	-	-	-	-	-
<b>3. Profit / (Loss) before tax (1-2)</b>	<b>243.07</b>	<b>234.65</b>	<b>(303.07)</b>	<b>473.61</b>	<b>(1,610.28)</b>
<b>4. Tax expense</b>					
Current Tax	48.26	42.54	-	90.79	-
Deferred Tax	(63.19)	(102.28)	(113.34)	(16.77)	(468.17)
Short / Excess income tax provision for earlier years	-	36.75	(9.74)	36.75	60.95
<b>5. Net Profit / (Loss) after tax (3-4)</b>	<b>258.00</b>	<b>257.65</b>	<b>(179.99)</b>	<b>362.84</b>	<b>(1,203.06)</b>
<b>6. Other Comprehensive Income</b>					
Items that will not be reclassified into Profit or Loss					
- Remeasurement of Defined Benefit Plans (Net of tax)	3.95	-	(0.87)	3.95	(1.25)
<b>7. Total Comprehensive Income for the year (after tax) (5+6)</b>	<b>261.95</b>	<b>257.65</b>	<b>(180.86)</b>	<b>366.78</b>	<b>(1,204.31)</b>
<b>8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)</b>	<b>4,067.27</b>	<b>4,067.27</b>	<b>2,286.44</b>	<b>4,067.27</b>	<b>2,286.44</b>
<b>9. Other Equity excluding Revaluation reserve as per Balance Sheet</b>				<b>10,079.29</b>	<b>8,243.33</b>
<b>10. Earnings per Equity Share (of Rs. 10/- each)</b>					
(a) Basic	0.89	1.03	(0.79)	1.26	(5.26)
(b) Diluted	0.89	1.03	(0.79)	1.26	(5.26)

**Notes :**

1) The Above Financial Results were reviewed by the audit committee of the board on 5th June, 2020 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed an unmodified opinion. The auditors report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.

2) Misc expenses for quarter ended 31st March 2020 have increased mainly on account of the provision/ payment of following- i. Impairment of assets: Rs.2.12 Cr (Previous 9 months: Nil); ii. GST reversal on account of voluntary payment: Rs.1.08 Cr (Previous 9 months: Rs.0.50 Cr) iii. Balances written off: Rs.1.54 cr (Previous 9 Months: Nil); iv. Processing charges: Rs.2.09 cr (Previous 9 months: Rs.1.19 cr)

3) Company has issued and allotted 1,78,08,219 Equity Shares of Rs.10 each at Rs.18.25/-per share including Rs.8.25 on account of share premium on 30th November 2019 to the promoter of the company Dr. Omkar Pravin Herlekar.

4) Finance cost includes Gain / (Loss) on account of foreign exchange fluctuations

Quarter / Half year ended	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
Foreign Exchange Gain / (Loss)	(107.25)	(15.46)	8.57	(160.01)	(151.16)

5) The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segment information is not applicable.

6) The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgements and estimates, including in relation to recoverability of receivables, assessment of impairment of goodwill and intangibles investments and inventory, based on the information available to date, while preparing the Company's financial results as of and for the year ended March 31, 2020

6) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.



By order of the Board of Directors  
For Lasasupergenerics Limited

Omkar Herlekar  
Chairman & Managing Director  
(DIN No. 01587154)

Place : Mumbai  
Date : 5th June, 2020

CIN : L24233MH2016PLC274202

(Rs. In Lakhs)


Particulars	As at 31 March 2020	As at 31 March 2019
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	14,595.67	15,566.29
Capital Work in Progress	-	695.79
Intangible assets	623.28	602.96
Intangible assets under development	-	25.10
<b>Financial Assets</b>		
Non Current Investments	-	-
Loans	75.15	73.65
Deferred Tax Assets	317.41	302.02
	<b>15,611.50</b>	<b>17,265.81</b>
<b>Current assets</b>		
Inventories	2,630.48	3,159.98
<b>Financial Assets</b>		
Trade receivables	2,064.83	2,887.94
Cash and cash equivalents	256.84	42.08
Bank balances other than cash & cash equivalents	349.37	226.42
Loans	5.00	5.00
Other current assets	2,280.85	2,262.29
	<b>7,587.36</b>	<b>8,583.70</b>
	<b>23,198.86</b>	<b>25,849.52</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity Share capital	4,067.27	2,286.44
Other Equity	10,079.29	8,243.33
	<b>14,146.56</b>	<b>10,529.77</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial Liabilities</b>		
Non Current Borrowings	1,414.24	4,572.24
Provisions	46.17	35.77
Deferred Tax Liabilities	-	-
	<b>1,460.41</b>	<b>4,608.02</b>
<b>Current liabilities</b>		
<b>Financial Liabilities</b>		
Current Borrowings	2,033.78	2,300.31
Trade payables	3,373.09	5,967.44
Other financial liabilities	1,393.15	1,587.02
Other current liabilities	295.33	607.87
Provisions	405.75	249.09
Current tax liabilities (net)	90.79	-
	<b>7,591.88</b>	<b>10,711.73</b>
	<b>23,198.86</b>	<b>25,849.52</b>


For Thanawala & Co.  
 Chartered Accountants  
 Firm Registration No.: 110948W

SD/-  
 CA Vijay Thanawala  
 (Proprietor)  
 M.No.: 15632

Place : Mumbai  
 Date : 5th June, 2020

For Lasa Supergenerics Limited

  
 Omkar Herlekar  
 (Chairman & Managing Director)  
 DIN:01587154

  
 Mithun Jadhav  
 (Whole Time Director)  
 DIN:08181048

**LASA SUPERGENERICS LIMITED**  
**CIN: L24233MH2016PLC274202**  
**Statement of Cash flows for the year ended March 31, 2020**

(Rs. In Lakhs)


Particulars	Year ended 31 March 2020	Year ended 31 March 2019
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net (loss) / profit before tax	473.61	(1,610.28)
<b>Adjustments for</b>		
Depreciation and Amortisation Expense	1,733.90	1,930.85
Finance Costs	810.42	1,202.12
Interest income	(23.16)	(411.69)
Remeasurement of employee defined benefit obligation	5.33	(1.69)
Provision for doubtful debts and advances (net)	-	-
<b>Operating profit before working capital changes</b>	<b>3,000.11</b>	<b>1,109.32</b>
<b>Working capital adjustments :-</b>		
(Increase) / Decrease in Trade and Other Receivables	823.10	1,327.17
(Increase) / Decrease in Inventories	529.50	1,063.47
(Increase) / Decrease in Loans	(1.50)	(1.24)
(Increase) / Decrease in Other Current Assets	(18.56)	(51.85)
Increase / (Decrease) in Trade and Other Payables	(2,594.35)	1,173.92
Increase / (Decrease) in Provisions	167.06	131.80
Increase / (Decrease) in Other Financial Liabilities	(193.87)	(69.06)
Increase / (Decrease) in Other Current Liabilities	(312.54)	(263.27)
<b>Cash generated from / (used in) operations</b>	<b>1,398.97</b>	<b>4,420.27</b>
Direct taxes paid (Net of Refunds)	(36.75)	(354.49)
<b>Net cash (used in) / from generated from operating activities</b>	<b>1,362.22</b>	<b>4,065.78</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant & equipment and intangible assets (including capital work-in-progress and capital advances)	(62.71)	(1,132.96)
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	(122.95)	(12.62)
Interest received	23.16	411.69
<b>Net cash (used in) / generated from investing activities</b>	<b>(162.51)</b>	<b>(733.89)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Issue of Share Capital ( Considered as deemed inflow)	1,780.83	(0.00)
Proceeds from Capital Reserve	1,469.18	-
Interest paid	(810.42)	(1,202.12)
Proceeds from long-term borrowings (net)	(3,158.00)	(1,454.75)
Proceeds from short-term borrowings (net)	(266.54)	(682.73)
Redemption of investment	-	0.10
<b>Net cash (used in) / from financing activities</b>	<b>(984.96)</b>	<b>(3,339.51)</b>
<b>Net decrease in cash and cash equivalents (A+B+C)</b>	<b>214.76</b>	<b>(7.61)</b>
Cash and cash equivalents at the beginning of the year	42.08	49.69
<b>Cash and cash equivalents at the end of the year</b>	<b>256.84</b>	<b>42.08</b>
<b>Components of cash and cash equivalents considered only for the purpose of cash flow statement</b>		
In bank current accounts in Indian rupees	200.89	33.72
Cash on hand	55.95	8.36
	<b>256.84</b>	<b>42.08</b>


**For Thanawala & Co.**  
Chartered Accountants  
Firm Registration No.: 110948W

**SD/-**  
**CA Vijay Thanawala**  
**(Proprietor)**  
M.No.: 15632

Place : Mumbai  
Date : 5th June, 2020

For Lasa Supergenerics Limited

  
**Omkar Herfekar**  
**(Chairman & Managing Director)**  
DIN:01587154

  
**Mithun Jadhav**  
**(Whole Time Director)**  
DIN:08181048